A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Bladder cancer; Breast cancer; Lung cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Therapeutic Use
- Sponsors Biocad
- 29 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 29 Aug 2018 Planned End Date changed from 1 Sep 2017 to 1 Nov 2018.
- 09 Mar 2017 Status changed from active, no longer recruiting to recruiting.